O	0	6	Safety
O	7	10	and
O	11	19	efficacy
O	20	22	of
O	23	34	alternating
O	35	44	treatment
O	45	49	with
B-intervention	50	56	EP2006
O	56	57	,
O	58	59	a
O	60	70	filgrastim
O	71	81	biosimilar
O	81	82	,
O	83	86	and
B-control	87	96	reference
I-control	97	107	filgrastim
O	107	108	:
O	109	110	a
O	111	116	phase
O	117	120	III
O	120	121	,
O	122	132	randomised
O	132	133	,
O	134	140	double
O	140	141	-
O	141	146	blind
O	147	155	clinical
O	156	161	study
O	162	164	in
O	165	168	the
O	169	179	prevention
O	180	182	of
B-condition	183	189	severe
I-condition	190	201	neutropenia
O	202	204	in
O	205	213	patients
O	214	218	with
O	219	225	breast
O	226	232	cancer
O	233	242	receiving
O	243	259	myelosuppressive
O	260	272	chemotherapy
O	272	273	.

O	274	276	In
O	277	281	2015
O	281	282	,
O	283	286	the
O	287	297	biosimilar
O	298	308	filgrastim
O	309	315	EP2006
O	316	322	became
O	323	326	the
O	327	332	first
O	333	343	biosimilar
O	344	352	approved
O	353	355	by
O	356	359	the
O	360	362	US
O	363	367	Food
O	368	371	and
O	372	376	Drug
O	377	391	Administration
O	392	395	for
O	396	406	commercial
O	407	410	use
O	411	413	in
O	414	417	the
O	418	424	United
O	425	431	States
O	431	432	,
O	433	441	marketed
O	442	444	as
O	445	451	Zarxio
O	451	452	®
O	453	454	(
O	454	460	Sandoz
O	460	461	)
O	461	462	.

O	463	467	This
O	468	473	phase
O	474	477	III
O	478	488	randomised
O	488	489	,
O	490	496	double
O	496	497	-
O	497	502	blind
O	503	515	registration
O	516	521	study
O	522	524	in
B-eligibility	525	533	patients
I-eligibility	534	538	with
I-eligibility	539	545	breast
I-eligibility	546	552	cancer
I-eligibility	553	562	receiving
I-eligibility	563	564	(
I-eligibility	564	567	neo
I-eligibility	567	568	)
I-eligibility	568	576	adjuvant
I-eligibility	577	593	myelosuppressive
I-eligibility	594	606	chemotherapy
I-eligibility	607	608	(
I-eligibility	608	611	TAC
I-eligibility	611	612	;
I-eligibility	613	622	docetaxel
I-eligibility	623	624	+
I-eligibility	625	636	doxorubicin
I-eligibility	637	638	+
I-eligibility	639	655	cyclophosphamide
I-eligibility	655	656	)
O	657	665	compares
O	666	675	reference
O	676	686	filgrastim
O	686	687	,
O	688	696	Neupogen
O	696	697	®
O	698	699	(
O	699	704	Amgen
O	704	705	)
O	705	706	,
O	707	711	with
O	712	715	two
O	716	722	groups
O	723	732	receiving
O	733	744	alternating
O	745	754	treatment
O	755	759	with
O	760	769	reference
O	770	773	and
O	774	784	biosimilar
O	785	790	every
O	791	796	other
O	797	802	cycle
O	802	803	.

O	804	805	A
O	806	811	total
O	812	814	of
B-total-participants	815	818	218
O	819	827	patients
O	828	837	receiving
O	838	839	5
O	840	841	µ
O	841	842	g
O	842	843	/
O	843	845	kg
O	845	846	/
O	846	849	day
O	850	860	filgrastim
O	861	865	over
O	866	869	six
O	870	882	chemotherapy
O	883	889	cycles
O	890	894	were
O	895	905	randomised
O	906	907	1
O	907	908	:
O	909	910	1
O	910	911	:
O	912	913	1
O	913	914	:
O	915	916	1
O	917	921	into
O	922	926	four
O	927	931	arms
O	931	932	.

O	933	936	Two
O	937	941	arms
O	942	950	received
O	951	955	only
O	956	959	one
O	960	967	product
O	967	968	,
O	969	979	biosimilar
O	980	982	or
O	983	992	reference
O	993	994	(
O	994	1004	unswitched
O	1004	1005	)
O	1005	1006	,
O	1007	1010	and
O	1011	1014	two
O	1015	1019	arms
O	1020	1021	(
O	1021	1029	switched
O	1029	1030	)
O	1031	1039	received
O	1040	1051	alternating
O	1052	1062	treatments
O	1063	1068	every
O	1069	1074	other
O	1075	1080	cycle
O	1081	1082	(
O	1082	1092	biosimilar
O	1093	1097	then
O	1098	1107	reference
O	1108	1110	or
O	1111	1115	vice
O	1116	1121	versa
O	1122	1126	over
O	1127	1130	six
O	1131	1137	cycles
O	1137	1138	)
O	1138	1139	.

O	1140	1145	Since
O	1146	1149	the
O	1150	1156	switch
O	1157	1165	occurred
O	1166	1170	from
O	1171	1176	cycle
O	1177	1178	2
O	1179	1186	onwards
O	1186	1187	,
O	1188	1192	this
O	1193	1201	analysis
O	1202	1210	compared
O	1211	1217	pooled
O	1218	1226	switched
O	1227	1233	groups
O	1234	1236	to
O	1237	1240	the
O	1241	1251	unswitched
O	1252	1261	reference
O	1262	1267	group
O	1268	1271	for
O	1272	1280	efficacy
O	1281	1287	during
O	1288	1294	cycles
O	1295	1296	2
O	1296	1297	-
O	1297	1298	6
O	1298	1299	.

O	1300	1306	Safety
O	1307	1310	was
O	1311	1315	also
O	1316	1324	assessed
O	1324	1325	.

O	1326	1329	Non
O	1329	1330	-
O	1330	1341	inferiority
O	1342	1344	in
O	1345	1352	febrile
O	1353	1364	neutropenia
O	1365	1366	(
O	1366	1368	FN
O	1368	1369	)
O	1370	1375	rates
O	1376	1383	between
O	1384	1390	groups
O	1391	1394	for
O	1395	1401	cycles
O	1402	1403	2
O	1403	1404	-
O	1404	1405	6
O	1406	1409	was
O	1410	1415	shown
O	1416	1418	if
O	1419	1421	95
O	1421	1422	%
O	1423	1427	were
O	1428	1434	within
O	1435	1436	a
O	1437	1440	pre
O	1440	1441	-
O	1441	1448	defined
O	1449	1455	margin
O	1456	1458	of
O	1459	1460	-
O	1461	1463	15
O	1463	1464	%
O	1464	1465	.

O	1466	1467	A
O	1468	1473	total
O	1474	1476	of
B-intervention-participants	1477	1480	109
O	1481	1489	patients
O	1490	1498	switched
O	1499	1508	treatment
O	1508	1509	,
O	1510	1513	and
B-control-participants	1514	1516	52
O	1517	1525	patients
O	1526	1534	received
O	1535	1544	reference
O	1545	1547	in
O	1548	1551	all
O	1552	1558	cycles
O	1558	1559	.

O	1560	1568	Baseline
O	1569	1584	characteristics
O	1585	1589	were
O	1590	1597	similar
O	1598	1605	between
O	1606	1612	groups
O	1612	1613	.

O	1614	1617	The
B-outcome	1618	1627	incidence
I-outcome	1628	1630	of
I-outcome	1631	1633	FN
O	1634	1637	was
B-cv-bin-percent	1638	1639	0
I-cv-bin-percent	1639	1640	%
O	1641	1642	(
O	1642	1651	reference
O	1651	1652	)
O	1653	1659	versus
B-iv-bin-percent	1660	1661	3
I-iv-bin-percent	1661	1662	.
I-iv-bin-percent	1662	1663	4
I-iv-bin-percent	1663	1664	%
O	1665	1666	(
O	1666	1667	n
O	1668	1669	=
B-iv-bin-abs	1670	1671	3
O	1671	1672	,
O	1673	1681	switched
O	1681	1682	)
O	1683	1689	across
O	1690	1696	cycles
O	1697	1698	2
O	1698	1699	-
O	1699	1700	6
O	1700	1701	,
O	1702	1706	with
O	1707	1708	a
O	1709	1719	difference
O	1720	1722	of
O	1723	1724	-
O	1725	1726	3
O	1726	1727	.
O	1727	1728	4
O	1728	1729	%
O	1730	1731	(
O	1731	1733	95
O	1733	1734	%
O	1735	1745	confidence
O	1746	1754	interval
O	1754	1755	:
O	1756	1757	-
O	1757	1758	9
O	1758	1759	.
O	1759	1761	65
O	1761	1762	%
O	1763	1765	to
O	1766	1767	4
O	1767	1768	.
O	1768	1770	96
O	1770	1771	%
O	1771	1772	)
O	1772	1773	,
O	1774	1781	showing
O	1782	1785	non
O	1785	1786	-
O	1786	1797	inferiority
O	1797	1798	.

B-outcome	1799	1809	Infections
O	1810	1818	occurred
O	1819	1821	in
B-iv-bin-percent	1822	1823	9
I-iv-bin-percent	1823	1824	.
I-iv-bin-percent	1824	1825	3
I-iv-bin-percent	1825	1826	%
O	1827	1828	(
O	1828	1836	switched
O	1836	1837	)
O	1838	1844	versus
B-cv-bin-percent	1845	1846	9
I-cv-bin-percent	1846	1847	.
I-cv-bin-percent	1847	1848	9
I-cv-bin-percent	1848	1849	%
O	1850	1851	(
O	1851	1860	reference
O	1860	1861	)
O	1861	1862	.

B-outcome	1863	1878	Hospitalisation
I-outcome	1879	1882	due
I-outcome	1883	1885	to
I-outcome	1886	1888	FN
O	1889	1892	was
O	1893	1896	low
O	1897	1898	(
B-iv-bin-abs	1898	1901	one
O	1902	1909	patient
O	1910	1912	in
O	1913	1918	cycle
O	1919	1920	6
O	1920	1921	;
O	1922	1930	switched
O	1930	1931	)
O	1931	1932	.

B-outcome	1933	1940	Adverse
I-outcome	1941	1947	events
O	1948	1955	related
O	1956	1958	to
O	1959	1969	filgrastim
O	1970	1974	were
O	1975	1983	reported
O	1984	1986	in
B-iv-bin-percent	1987	1989	42
I-iv-bin-percent	1989	1990	.
I-iv-bin-percent	1990	1991	1
I-iv-bin-percent	1991	1992	%
O	1993	1994	(
O	1994	2002	switched
O	2002	2003	)
O	2004	2010	versus
B-cv-bin-percent	2011	2013	39
I-cv-bin-percent	2013	2014	.
I-cv-bin-percent	2014	2015	2
I-cv-bin-percent	2015	2016	%
O	2017	2018	(
O	2018	2027	reference
O	2027	2028	)
O	2029	2030	(
O	2030	2033	all
O	2034	2040	cycles
O	2040	2041	)
O	2041	2042	.

B-outcome	2043	2058	Musculoskeletal
I-outcome	2058	2059	/
I-outcome	2059	2069	connective
I-outcome	2070	2076	tissue
I-outcome	2077	2086	disorders
O	2087	2094	related
O	2095	2097	to
O	2098	2108	filgrastim
O	2109	2117	occurred
O	2118	2120	in
B-iv-bin-percent	2121	2123	35
I-iv-bin-percent	2123	2124	.
I-iv-bin-percent	2124	2125	5
I-iv-bin-percent	2125	2126	%
O	2127	2128	(
O	2128	2136	switched
O	2136	2137	)
O	2138	2144	versus
B-cv-bin-percent	2145	2147	39
I-cv-bin-percent	2147	2148	.
I-cv-bin-percent	2148	2149	2
I-cv-bin-percent	2149	2150	%
O	2151	2152	(
O	2152	2161	reference
O	2161	2162	)
O	2163	2164	(
O	2164	2167	all
O	2168	2174	cycles
O	2174	2175	)
O	2175	2176	,
O	2177	2186	including
B-outcome	2187	2191	bone
I-outcome	2192	2196	pain
O	2197	2198	(
B-iv-bin-percent	2198	2200	30
I-iv-bin-percent	2200	2201	.
I-iv-bin-percent	2201	2202	8
I-iv-bin-percent	2202	2203	%
O	2204	2210	versus
B-cv-bin-percent	2211	2213	33
I-cv-bin-percent	2213	2214	.
I-cv-bin-percent	2214	2215	3
I-cv-bin-percent	2215	2216	%
O	2216	2217	)
O	2217	2218	.

O	2219	2221	No
B-outcome	2222	2234	neutralising
I-outcome	2235	2245	antibodies
O	2246	2250	were
O	2251	2259	detected
O	2259	2260	.

O	2261	2266	There
O	2267	2271	were
O	2272	2274	no
O	2275	2285	clinically
O	2286	2296	meaningful
O	2297	2304	results
O	2305	2314	regarding
O	2315	2323	efficacy
O	2323	2324	,
O	2325	2331	safety
O	2332	2334	or
O	2335	2349	immunogenicity
O	2350	2354	when
O	2355	2364	switching
O	2365	2369	from
O	2370	2379	reference
O	2380	2382	to
O	2383	2393	biosimilar
O	2394	2404	filgrastim
O	2404	2405	/
O	2405	2411	EP2006
O	2411	2412	,
O	2413	2415	or
O	2416	2420	vice
O	2421	2426	versa
O	2426	2427	.
